<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42564">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552225</url>
  </required_header>
  <id_info>
    <org_study_id>H 34438</org_study_id>
    <nct_id>NCT02552225</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Laryngitis With Amitriptyline</brief_title>
  <official_title>Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Laryngological Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the effectiveness of amitriptyline versus placebo (inactive
      medication) in treating chronic laryngitis. At the baseline visit, subjects will be assigned
      at random to amitriptyline or placebo which they will take for 8 weeks. Subjects will be
      seen in the clinic at baseline and at 8 weeks. Improvement will be measured using
      standardized symptom scales, and a self-reported subjective improvement percentage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on modified Reflux Symptom Index (RSI)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on modified Voice Handicap Index-10 (VHI-10)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with side effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients discontinuing treatment due to side effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective percentage improvement in symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will subjectively rate improvement in symptoms by percentage comparing pre-treatment to post-treatment symptoms after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effect by category</measure>
    <time_frame>8 weeks</time_frame>
    <description>patients will describe subjective side effects experienced, such as dry mouth, sedation, dizziness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Laryngeal Diseases</condition>
  <arm_group>
    <arm_group_label>amitriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amitriptyline</intervention_name>
    <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
    <arm_group_label>amitriptyline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be age 18 or older and able to consent for themselves

          2. Must have had structural pathology such as tumor previously ruled out using flexible
             laryngoscopy

          3. Must be able to speak and read the English language

          4. Must have failed a 2 month or longer trial of a proton pump inhibitor for the
             treatment of gastro-esophageal reflux

          5. Women under 55 years of age who may become pregnant must have a negative pregnancy
             test and agree to barrier or hormonal methods of contraception during the study

        Exclusion Criteria:

          1. Environmental allergies

          2. Smoking within past 5 years

          3. Upper respiratory infections within the past 2 months

          4. Use of narcotics (e.g. oxycodone, methadone) within the past week

          5. Any prior history of amitryptiline use

          6. Use of any other monoamine oxidase inhibitors (MAOIs) other than amitryptiline within
             the past 4 weeks (selegiline, phenelzine, tranylcypromine, isocarboxazid, rasagiline,
             phenelzine sulfate, selegiline hydrochloride, rasagiline mesylate, tranylcypromine
             sulfate)

          7. History of urinary retention

          8. Any history of major depressive disorder

          9. Any prior history of allergy to a tricyclic antidepressant

         10. Current diagnosis of gastroesophageal reflux (GERD)

         11. For women 18-55 years of age without history of menopause: currently nursing or
             pregnant, plans to become pregnant, or unwillingness to utilize contraception
             (barrier or hormonal methods)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Pieter Noordzij, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J. Pieter Noordzij, MD</last_name>
    <email>pieter.noordzij@bmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Pieter Noordzij, MD</last_name>
      <email>pieter.noordzij@bmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Minyoung Jang, MD</last_name>
      <email>minyoung.jang@bmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>J. Pieter Noordzij, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 7, 2016</lastchanged_date>
  <firstreceived_date>September 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>J Pieter Noordzij</investigator_full_name>
    <investigator_title>BMC Attending Physician</investigator_title>
  </responsible_party>
  <keyword>laryngeal sensory neuropathy, chronic laryngeal neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Laryngitis</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
